If one could sweep the brain clean and send the toxic substances that drive neurodegeneration to the recycling bin, perhaps one could treat Alzheimer’s disease (AD). Researchers at the Chinese Academy of Sciences propose a new therapeutic strategy that uses synthetic peptides that bind to amyloid-β (Aβ) and direct it toward lysosomes. In addition, researchers at the Washington University School of Medicine in St. Louis have genetically modified astrocytes in vivo to express chimeric antigen receptors (CARs) that recognize and phagocytose Aβ plaques. Read More

A recent study published in Cancer Research by scientists at The University of Texas MD Anderson Cancer Center (USA) and collaborators aimed to identify and characterize a target that elicits an anticancer response through both disrupting cancer cell redox homeostasis and increasing the immunogenicity of pancreatic ductal adenocarcinoma (PDAC). Read More

Harbour Biomed Ltd. and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. have announced IND approval by China’s National Medical Products Administration (NMPA) for HBM-7575 (SKB-575) for the treatment of atopic dermatitis. Read More

Dysregulation of the mechanistic target of rapamycin (mTOR) signaling pathway is frequently observed across a wide range of cancers and contributes to uncontrolled cell proliferation, enhanced cellular metabolism, and tumor progression. Read More

Zelluna ASA has established a collaboration with Etcembly Ltd. that will focus on the engineering of high-affinity, tumor-specific T-cell receptors targeting KKLC1. Read More

Newcelx Ltd. has entered into a collaborative research agreement with Eledon Pharmaceuticals Inc. with the aim of advancing its lead program, NCEL-101, for type 1 diabetes. Read More

Researchers from Hangzhou Innogate Pharma Co. Ltd. and Innorace Biopharma Co. Ltd. have disclosed tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or tyrosine-protein phosphatase non-receptor type 2 (PTPN2; TCPTP) inhibitors. They are reported to be useful for the treatment of cancer, metabolic dysfunction-associated steatotic liver disease (MASLD; NAFLD), obesity and diabetes. Read More

In developed countries, up to 20% of the population suffers from pollen allergies to birch and related trees. Mabylon AG has developed an anti-tree pollen antibody therapeutic, MY-010, that targets several inducers of spring hay fever, such as birch, alder and hazel, among others. Read More

Jiangxi Kerui Pharmaceutical Co. Ltd. has patented potassium voltage-gated channel subfamily KQT member 2/3 (KCNQ2/3) activators. They are reported to be useful for the treatment of anxiety disorders, depression, pain, focal seizures and tonic clonic epilepsy. Read More

Shanghai Chempartner Co. Ltd. has identified antibody-drug conjugates (ADCs) comprising HER2 (erbB2) or tumor-associated calcium signal transducer 2 (TACSTD2; TROP2) covalently linked to eribulin through a linker reported to be useful for the treatment of cancer. Read More

Recent findings have shown that fatty acid synthase (FASN) is a promising therapeutic target in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD) due to its involvement in de novo lipogenesis. Chinese researchers have recently published data on a FASN inhibitor, 84-B10, for the potential treatment of MASLD. Read More

Scientists from Fu Wai Hospital of the Chinese Academy of Medical Sciences and Shenzhen Bay Laboratory have divulged cAMP-specific 3',5'-cyclic phosphodiesterase 4B (PDE4B) inhibitors. They are reported to be useful for the treatment of autoimmune diseases, cancer, neurological disorder, diabetes, inflammatory bowel disease, pulmonary fibrosis, psoriasis and arthritis, among others. Read More

Shanghai Deep Potential Technology Co. Ltd. has discovered serine/threonine-protein kinase PLK1 (STPK13) inhibitors reported to be useful for the treatment of cancer. Read More

In a recent publication in Biomedicine & Pharmacotherapy, investigators evaluated the activity of a 7-amino-acid peptide, EB-203, using a zebrafish model of diabetic retinopathy (DR)-like vascular alterations. Read More